Biotech Archives - Page 5 of 795

1 minute read

Mirum’s Volixibat Achieves Interim Analyses In VANTAGE PBC And VISTAS PSC Studies; Showed 3.8 Point Reduction From Baseline And 2.3 Point Placebo-Adjusted Reduction In Primary Endpoint Of Pruritus

June 17, 8:11 AM

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus- VISTAS PSC interim analysis exceeds efficacy threshold for study

MIRM

1 minute read

Tonix Pharmaceuticals Presented Poster Of Tonmya For The Management Of Fibromyalgia At The Annual EULAR 2024

By Benzinga Newsdesk

June 17, 8:09 AM

Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain and demonstrated broad fibromyalgia symptom improvement, as demonstrated by

TNXP

1 minute read

Centers For Medicare & Medicaid Services Issues ICD-10-PCS Codes For Humacyte’s Human Acellular Vessel

By Benzinga Newsdesk

June 17, 8:06 AM

– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte's HAV – – BLA submission under Priority Review by FDA for the treatment of

HUMA

1 minute read

Rallybio Presents Results Of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially And Ethnically Diverse Populations

By Benzinga Newsdesk

June 17, 8:05 AM

– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries –– Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and the

RLYB

2 minute read

AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer

By Vandana Singh

June 17, 5:32 AM

AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymphoma patients over 65.

AZN

2 minute read

EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says

By Vandana Singh

June 17, 3:22 AM

Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.

FEMY

3 minute read

EXCLUSIVE: ‘Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,’ Petros Pharma President Says

By Vandana Singh

June 17, 3:08 AM

Petros Pharmaceuticals specializes in men's health therapeutics. President Fady Boctor discusses the company's strategy to make key prescription medications. Petros is poised to expand within the $66.5 billion Rx-to-OTC market projected by 2033.

PTPI

1 minute read

FDA
News

Scilex Holding Announces Publication Of Trial Results For SP-102 (SEMDEXA) In PAIN Journal; Focuses On Non-Opioid Pain Management Products For Acute And Chronic Pain

By Benzinga Newsdesk

June 14, 1:43 PM

The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for the Study of

SCLX

1 minute read

Actinium Presents Oral Presentation Featuring Improved Outcomes In TP53 Patients Receiving Iomab-B In The Phase 3 SIERRA Trial At EHA 2024 Annual Congress

By Benzinga Newsdesk

June 14, 8:41 AM

- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard

ATNM